Ligand Pharmaceuticals (LGND) reported Q4 core adjusted net income Thursday of $1.27 per diluted share, up from $1.05 a year earlier.
Analysts polled by FactSet expected $1.19.
Total revenue for the quarter ended Dec. 31 was $42.8 million, up from $28.1 million a year earlier.
Analysts surveyed by FactSet expected $39 million.
The company expects full year 2025 adjusted earnings in a range of $6.00 to $6.25 per diluted share on total revenue of $180 million to $200 million. Analysts polled by FactSet expect adjusted earnings of $6.07 per diluted share on total revenue of $187.1 million.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。